ID   KCNA2_RAT               Reviewed;         499 AA.
AC   P63142; P15386; Q02010;
DT   13-SEP-2004, integrated into UniProtKB/Swiss-Prot.
DT   13-SEP-2004, sequence version 1.
DT   02-OCT-2024, entry version 172.
DE   RecName: Full=Potassium voltage-gated channel subfamily A member 2;
DE   AltName: Full=RAK;
DE   AltName: Full=RBK2 {ECO:0000303|PubMed:2722779};
DE   AltName: Full=RCK5 {ECO:0000303|PubMed:2555158};
DE   AltName: Full=Voltage-gated potassium channel subunit Kv1.2;
GN   Name=Kcna2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=2722779; DOI=10.1016/s0021-9258(18)83173-8;
RA   McKinnon D.;
RT   "Isolation of a cDNA clone coding for a putative second potassium channel
RT   indicates the existence of a gene family.";
RL   J. Biol. Chem. 264:8230-8236(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, ACTIVITY
RP   REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND TRANSPORTER ACTIVITY.
RC   TISSUE=Brain;
RX   PubMed=2555158; DOI=10.1002/j.1460-2075.1989.tb08483.x;
RA   Stuehmer W., Ruppersberg J.P., Schroerter K.H., Sakmann B., Stocker M.,
RA   Giese K.P., Perschke A., Baumann A., Pongs O.;
RT   "Molecular basis of functional diversity of voltage-gated potassium
RT   channels in mammalian brain.";
RL   EMBO J. 8:3235-3244(1989).
RN   [3]
RP   SEQUENCE REVISION.
RA   Ludwig J.;
RL   Submitted (MAR-1996) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND TRANSPORTER ACTIVITY.
RC   TISSUE=Heart atrium;
RX   PubMed=1715584; DOI=10.1073/pnas.88.17.7892;
RA   Paulmichl M., Nasmith P., Herllmiss R., Reed K., Boyle W.A., Nerbonne J.M.,
RA   Peralta E.G., Clapham D.E.;
RT   "Cloning and expression of a rat cardiac delayed rectifier potassium
RT   channel.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:7892-7895(1991).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, INTERACTION WITH KCNA4, ACTIVITY
RP   REGULATION, AND TRANSPORTER ACTIVITY.
RX   PubMed=8495559; DOI=10.1161/01.res.72.6.1326;
RA   Po S., Roberds S., Snyders D.J., Tamkun M.M., Bennett P.B.;
RT   "Heteromultimeric assembly of human potassium channels. Molecular basis of
RT   a transient outward current?";
RL   Circ. Res. 72:1326-1336(1993).
RN   [6]
RP   ACTIVITY REGULATION.
RX   PubMed=8355670;
RA   Werkman T.R., Gustafson T.A., Rogowski R.S., Blaustein M.P., Rogawski M.A.;
RT   "Tityustoxin-K alpha, a structurally novel and highly potent K+ channel
RT   peptide toxin, interacts with the alpha-dendrotoxin binding site on the
RT   cloned Kv1.2 K+ channel.";
RL   Mol. Pharmacol. 44:430-436(1993).
RN   [7]
RP   SUBUNIT, INTERACTION WITH KCNA4, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=8361540; DOI=10.1038/365072a0;
RA   Sheng M., Liao Y.J., Jan Y.N., Jan L.Y.;
RT   "Presynaptic A-current based on heteromultimeric K+ channels detected in
RT   vivo.";
RL   Nature 365:72-75(1993).
RN   [8]
RP   INTERACTION WITH DLG1; DLG2 AND DLG4, AND TISSUE SPECIFICITY.
RX   PubMed=7477295; DOI=10.1038/378085a0;
RA   Kim E., Niethammer M., Rothschild A., Jan Y.N., Sheng M.;
RT   "Clustering of Shaker-type K+ channels by interaction with a family of
RT   membrane-associated guanylate kinases.";
RL   Nature 378:85-88(1995).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION, AND TRANSPORTER ACTIVITY.
RC   TISSUE=Brain;
RX   PubMed=7544443; DOI=10.1038/376737a0;
RA   Lev S., Moreno H., Martinez R., Canoll P., Peles E., Musacchio J.M.,
RA   Plowman G.D., Rudy B., Schlessinger J.;
RT   "Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion
RT   channel and MAP kinase functions.";
RL   Nature 376:737-745(1995).
RN   [10]
RP   FUNCTION, INTERACTION WITH RHOA, AND TRANSPORTER ACTIVITY.
RX   PubMed=9635436; DOI=10.1016/s0092-8674(00)81212-x;
RA   Cachero T.G., Morielli A.D., Peralta E.G.;
RT   "The small GTP-binding protein RhoA regulates a delayed rectifier potassium
RT   channel.";
RL   Cell 93:1077-1085(1998).
RN   [11]
RP   INTERACTION WITH CNTNAP2, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=10624965; DOI=10.1016/s0896-6273(00)81049-1;
RA   Poliak S., Gollan L., Martinez R., Custer A., Einheber S., Salzer J.L.,
RA   Trimmer J.S., Shrager P., Peles E.;
RT   "Caspr2, a new member of the neurexin superfamily, is localized at the
RT   juxtaparanodes of myelinated axons and associates with K+ channels.";
RL   Neuron 24:1037-1047(1999).
RN   [12]
RP   SUBCELLULAR LOCATION, SUBUNIT, INTERACTION WITH KCNAB2; KCNA1 AND KCNA4,
RP   AND GLYCOSYLATION.
RX   PubMed=10896669; DOI=10.1074/jbc.m005010200;
RA   Manganas L.N., Trimmer J.S.;
RT   "Subunit composition determines Kv1 potassium channel surface expression.";
RL   J. Biol. Chem. 275:29685-29693(2000).
RN   [13]
RP   SUBCELLULAR LOCATION, INTERACTION WITH KCNA1 AND KCNAB2, SUBUNIT, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=11086297;
RX   DOI=10.1002/1096-9861(20000101)429:1<166::aid-cne13>3.0.co;2-y;
RA   Rasband M.N., Trimmer J.S.;
RT   "Subunit composition and novel localization of K+ channels in spinal
RT   cord.";
RL   J. Comp. Neurol. 429:166-176(2001).
RN   [14]
RP   INTERACTION WITH PTK2B, AND PHOSPHORYLATION.
RX   PubMed=11739373; DOI=10.1074/jbc.m104726200;
RA   Byron K.L., Lucchesi P.A.;
RT   "Signal transduction of physiological concentrations of vasopressin in A7r5
RT   vascular smooth muscle cells. A role for PYK2 and tyrosine phosphorylation
RT   of K+ channels in the stimulation of Ca2+ spiking.";
RL   J. Biol. Chem. 277:7298-7307(2002).
RN   [15]
RP   FUNCTION, PHOSPHORYLATION, INTERACTION WITH CTTN, SUBCELLULAR LOCATION,
RP   TOPOLOGY, AND MUTAGENESIS OF TYR-415 AND TYR-417.
RX   PubMed=12151401; DOI=10.1074/jbc.m205005200;
RA   Hattan D., Nesti E., Cachero T.G., Morielli A.D.;
RT   "Tyrosine phosphorylation of Kv1.2 modulates its interaction with the
RT   actin-binding protein cortactin.";
RL   J. Biol. Chem. 277:38596-38606(2002).
RN   [16]
RP   FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND SUBUNIT.
RX   PubMed=12177193; DOI=10.1523/jneurosci.22-16-06953.2002;
RA   Dodson P.D., Barker M.C., Forsythe I.D.;
RT   "Two heteromeric Kv1 potassium channels differentially regulate action
RT   potential firing.";
RL   J. Neurosci. 22:6953-6961(2002).
RN   [17]
RP   INDUCTION BY HYPOXIA, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   PHOSPHORYLATION.
RX   PubMed=14713306; DOI=10.1046/j.1471-4159.2003.02110.x;
RA   Qiu M.H., Zhang R., Sun F.Y.;
RT   "Enhancement of ischemia-induced tyrosine phosphorylation of Kv1.2 by
RT   vascular endothelial growth factor via activation of phosphatidylinositol
RT   3-kinase.";
RL   J. Neurochem. 87:1509-1517(2003).
RN   [18]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=12777451; DOI=10.1113/jphysiol.2003.046250;
RA   Dodson P.D., Billups B., Rusznak Z., Szucs G., Barker M.C., Forsythe I.D.;
RT   "Presynaptic rat Kv1.2 channels suppress synaptic terminal
RT   hyperexcitability following action potential invasion.";
RL   J. Physiol. (Lond.) 550:27-33(2003).
RN   [19]
RP   SUBUNIT, INTERACTION WITH KCNA4, AND TISSUE SPECIFICITY.
RX   PubMed=12632190; DOI=10.1007/s00424-002-0994-7;
RA   Fergus D.J., Martens J.R., England S.K.;
RT   "Kv channel subunits that contribute to voltage-gated K+ current in renal
RT   vascular smooth muscle.";
RL   Pflugers Arch. 445:697-704(2003).
RN   [20]
RP   INDUCTION BY HYPOXIA.
RX   PubMed=15151918; DOI=10.1165/rcmb.2003-0386oc;
RA   Hong Z., Weir E.K., Nelson D.P., Olschewski A.;
RT   "Subacute hypoxia decreases voltage-activated potassium channel expression
RT   and function in pulmonary artery myocytes.";
RL   Am. J. Respir. Cell Mol. Biol. 31:337-343(2004).
RN   [21]
RP   FUNCTION, SUBCELLULAR LOCATION, AND SUBUNIT.
RX   PubMed=15618540; DOI=10.1161/01.res.0000154070.06421.25;
RA   Plane F., Johnson R., Kerr P., Wiehler W., Thorneloe K., Ishii K., Chen T.,
RA   Cole W.;
RT   "Heteromultimeric Kv1 channels contribute to myogenic control of arterial
RT   diameter.";
RL   Circ. Res. 96:216-224(2005).
RN   [22]
RP   FUNCTION.
RX   PubMed=16210348; DOI=10.1113/jphysiol.2005.098053;
RA   Khavandgar S., Walter J.T., Sageser K., Khodakhah K.;
RT   "Kv1 channels selectively prevent dendritic hyperexcitability in rat
RT   Purkinje cells.";
RL   J. Physiol. (Lond.) 569:545-557(2005).
RN   [23]
RP   FUNCTION.
RX   PubMed=16306173; DOI=10.1152/jn.01004.2005;
RA   Finnegan T.F., Chen S.R., Pan H.L.;
RT   "Mu opioid receptor activation inhibits GABAergic inputs to basolateral
RT   amygdala neurons through Kv1.1/1.2 channels.";
RL   J. Neurophysiol. 95:2032-2041(2006).
RN   [24]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, GLYCOSYLATION AT ASN-207, AND
RP   MUTAGENESIS OF ASN-207; SER-356; SER-360 AND THR-383.
RX   PubMed=16770729; DOI=10.1007/s11064-006-9056-4;
RA   Fujita T., Utsunomiya I., Ren J., Matsushita Y., Kawai M., Sasaki S.,
RA   Hoshi K., Miyatake T., Taguchi K.;
RT   "Glycosylation and cell surface expression of Kv1.2 potassium channel are
RT   regulated by determinants in the pore region.";
RL   Neurochem. Res. 31:589-596(2006).
RN   [25]
RP   SUBCELLULAR LOCATION, GLYCOSYLATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=17324383; DOI=10.1016/j.brainres.2007.01.092;
RA   Watanabe I., Zhu J., Sutachan J.J., Gottschalk A., Recio-Pinto E.,
RA   Thornhill W.B.;
RT   "The glycosylation state of Kv1.2 potassium channels affects trafficking,
RT   gating, and simulated action potentials.";
RL   Brain Res. 1144:1-18(2007).
RN   [26]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-252.
RX   PubMed=17766348; DOI=10.1529/biophysj.107.116160;
RA   Rezazadeh S., Kurata H.T., Claydon T.W., Kehl S.J., Fedida D.;
RT   "An activation gating switch in Kv1.2 is localized to a threonine residue
RT   in the S2-S3 linker.";
RL   Biophys. J. 93:4173-4186(2007).
RN   [27]
RP   REVIEW.
RX   PubMed=17917103; DOI=10.1007/s12035-007-8001-0;
RA   Baranauskas G.;
RT   "Ionic channel function in action potential generation: current
RT   perspective.";
RL   Mol. Neurobiol. 35:129-150(2007).
RN   [28]
RP   FUNCTION.
RX   PubMed=17869444; DOI=10.1016/j.neuroscience.2007.08.007;
RA   Yang Q., Chen S.R., Li D.P., Pan H.L.;
RT   "Kv1.1/1.2 channels are downstream effectors of nitric oxide on synaptic
RT   GABA release to preautonomic neurons in the paraventricular nucleus.";
RL   Neuroscience 149:315-327(2007).
RN   [29]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-440 AND SER-449,
RP   IDENTIFICATION BY MASS SPECTROMETRY, INTERACTION WITH KCNAB2, AND
RP   MUTAGENESIS OF THR-46; SER-440 AND SER-449.
RX   PubMed=18003609; DOI=10.1074/jbc.m708875200;
RA   Connors E.C., Ballif B.A., Morielli A.D.;
RT   "Homeostatic regulation of Kv1.2 potassium channel trafficking by cyclic
RT   AMP.";
RL   J. Biol. Chem. 283:3445-3453(2008).
RN   [30]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 267-PHE--PHE-302.
RX   PubMed=18638484; DOI=10.1016/j.jmb.2008.06.085;
RA   Tao X., MacKinnon R.;
RT   "Functional analysis of Kv1.2 and paddle chimera Kv channels in planar
RT   lipid bilayers.";
RL   J. Mol. Biol. 382:24-33(2008).
RN   [31]
RP   FUNCTION, SUBUNIT, AND INTERACTION WITH KCNAB1.
RX   PubMed=19713757; DOI=10.4161/chan.3.5.9558;
RA   Peters C.J., Vaid M., Horne A.J., Fedida D., Accili E.A.;
RT   "The molecular basis for the actions of Kvbeta1.2 on the opening and
RT   closing of the Kv1.2 delayed rectifier channel.";
RL   Channels 3:314-322(2009).
RN   [32]
RP   SUBCELLULAR LOCATION.
RX   PubMed=19403695; DOI=10.1091/mbc.e08-10-1074;
RA   Stirling L., Williams M.R., Morielli A.D.;
RT   "Dual roles for RHOA/RHO-kinase in the regulated trafficking of a voltage-
RT   sensitive potassium channel.";
RL   Mol. Biol. Cell 20:2991-3002(2009).
RN   [33]
RP   FUNCTION, SUBCELLULAR LOCATION, AND ACTIVITY REGULATION.
RX   PubMed=20805574; DOI=10.1085/jgp.200910398;
RA   Al-Sabi A., Shamotienko O., Dhochartaigh S.N., Muniyappa N., Le Berre M.,
RA   Shaban H., Wang J., Sack J.T., Dolly J.O.;
RT   "Arrangement of Kv1 alpha subunits dictates sensitivity to
RT   tetraethylammonium.";
RL   J. Gen. Physiol. 136:273-282(2010).
RN   [34]
RP   FUNCTION, INTERACTION WITH ADAM22 AND DLG4, SUBCELLULAR LOCATION,
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND TISSUE SPECIFICITY.
RX   PubMed=20089912; DOI=10.1523/jneurosci.4661-09.2010;
RA   Ogawa Y., Oses-Prieto J., Kim M.Y., Horresh I., Peles E., Burlingame A.L.,
RA   Trimmer J.S., Meijer D., Rasband M.N.;
RT   "ADAM22, a Kv1 channel-interacting protein, recruits membrane-associated
RT   guanylate kinases to juxtaparanodes of myelinated axons.";
RL   J. Neurosci. 30:1038-1048(2010).
RN   [35]
RP   FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, PHOSPHORYLATION AT
RP   TYR-458, AND MUTAGENESIS OF TYR-458.
RX   PubMed=21602278; DOI=10.1074/jbc.m111.219113;
RA   Gu C., Gu Y.;
RT   "Clustering and activity tuning of Kv1 channels in myelinated hippocampal
RT   axons.";
RL   J. Biol. Chem. 286:25835-25847(2011).
RN   [36]
RP   FUNCTION.
RX   PubMed=21647367; DOI=10.1371/journal.pone.0020402;
RA   Martel P., Leo D., Fulton S., Berard M., Trudeau L.E.;
RT   "Role of Kv1 potassium channels in regulating dopamine release and
RT   presynaptic D2 receptor function.";
RL   PLoS ONE 6:E20402-E20402(2011).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-440; SER-441 AND SER-468, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [38]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF VAL-381.
RX   PubMed=23725331; DOI=10.1042/bj20130297;
RA   Al-Sabi A., Kaza S.K., Dolly J.O., Wang J.;
RT   "Pharmacological characteristics of Kv1.1- and Kv1.2-containing channels
RT   are influenced by the stoichiometry and positioning of their alpha
RT   subunits.";
RL   Biochem. J. 454:101-108(2013).
RN   [39]
RP   FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, AND IDENTIFICATION IN A COMPLEX
RP   WITH KCNA1 AND KCNAB2.
RX   PubMed=23318870; DOI=10.1113/jphysiol.2012.249706;
RA   Ovsepian S.V., Steuber V., Le Berre M., O'Hara L., O'Leary V.B.,
RA   Dolly J.O.;
RT   "A defined heteromeric KV1 channel stabilizes the intrinsic pacemaking and
RT   regulates the output of deep cerebellar nuclear neurons to thalamic
RT   targets.";
RL   J. Physiol. (Lond.) 591:1771-1791(2013).
RN   [40]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=24472174; DOI=10.1186/1744-8069-10-8;
RA   Fan L., Guan X., Wang W., Zhao J.Y., Zhang H., Tiwari V., Hoffman P.N.,
RA   Li M., Tao Y.X.;
RT   "Impaired neuropathic pain and preserved acute pain in rats overexpressing
RT   voltage-gated potassium channel subunit Kv1.2 in primary afferent
RT   neurons.";
RL   Mol. Pain 10:8-8(2014).
RN   [41]
RP   SITE VAL-381.
RX   PubMed=25514171; DOI=10.1016/j.bcp.2014.12.002;
RA   Wang X., Umetsu Y., Gao B., Ohki S., Zhu S.;
RT   "Mesomartoxin, a new K(v)1.2-selective scorpion toxin interacting with the
RT   channel selectivity filter.";
RL   Biochem. Pharmacol. 93:232-239(2015).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 33-119 OF WILD-TYPE AND MUTANT
RP   VAL-46, FUNCTION, SUBUNIT, REGION, DOMAIN, AND MUTAGENESIS OF ARG-34;
RP   ASN-38; SER-40; GLY-41; LEU-42; ARG-43; PHE-44; GLU-45; THR-46; GLN-47;
RP   THR-50; ASP-70; ARG-73; GLU-75; PHE-77; ASP-79; ASN-81; ARG-82; ASP-86;
RP   LEU-89; TYR-90; GLN-93; ARG-97; ARG-99; VAL-102; ASN-103; PRO-105; ASP-107;
RP   ILE-108 AND GLU-111.
RX   PubMed=11007484; DOI=10.1016/s0092-8674(00)00088-x;
RA   Minor D.L. Jr., Lin Y.-F., Mobley B.C., Avelar A., Jan Y.N., Jan L.Y.,
RA   Berger J.M.;
RT   "The polar T1 interface is linked to conformational changes that open the
RT   voltage-gated potassium channel.";
RL   Cell 102:657-670(2000).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) IN COMPLEX WITH KCNAB2, SUBCELLULAR
RP   LOCATION, TOPOLOGY, SUBUNIT, AND INTERACTION WITH KCNAB2.
RX   PubMed=16002581; DOI=10.1126/science.1116269;
RA   Long S.B., Campbell E.B., Mackinnon R.;
RT   "Crystal structure of a mammalian voltage-dependent Shaker family K+
RT   channel.";
RL   Science 309:897-903(2005).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) IN COMPLEX WITH KCNAB2, AND DOMAIN.
RX   PubMed=16002579; DOI=10.1126/science.1116270;
RA   Long S.B., Campbell E.B., Mackinnon R.;
RT   "Voltage sensor of Kv1.2: structural basis of electromechanical coupling.";
RL   Science 309:903-908(2005).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF PADDLE CHIMERA MUTANT IN COMPLEX
RP   WITH KCNAB2, FUNCTION, SUBUNIT, INTERACTION WITH KCNAB2, SUBCELLULAR
RP   LOCATION, AND TOPOLOGY.
RX   PubMed=18004376; DOI=10.1038/nature06265;
RA   Long S.B., Tao X., Campbell E.B., MacKinnon R.;
RT   "Atomic structure of a voltage-dependent K+ channel in a lipid membrane-
RT   like environment.";
RL   Nature 450:376-382(2007).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) IN COMPLEX WITH KCNAB2, INTERACTION
RP   WITH KCNAB2, SUBUNIT, SUBCELLULAR LOCATION, AND TOPOLOGY.
RX   PubMed=20534430; DOI=10.1073/pnas.1000142107;
RA   Chen X., Wang Q., Ni F., Ma J.;
RT   "Structure of the full-length Shaker potassium channel Kv1.2 by normal-
RT   mode-based X-ray crystallographic refinement.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:11352-11357(2010).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 1-266 AND 303-499 IN COMPLEX WITH
RP   KCNAB2, SUBUNIT, INTERACTION WITH KCNAB2, SUBCELLULAR LOCATION, AND
RP   TOPOLOGY.
RX   PubMed=20360102; DOI=10.1126/science.1185954;
RA   Tao X., Lee A., Limapichat W., Dougherty D.A., MacKinnon R.;
RT   "A gating charge transfer center in voltage sensors.";
RL   Science 328:67-73(2010).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF PADDLE CHIMERA MUTANT IN COMPLEX
RP   WITH KCNAB2 AND CHARYBDOTOXIN, INTERACTION WITH KCNAB2, SUBUNIT,
RP   SUBCELLULAR LOCATION, AND TOPOLOGY.
RX   PubMed=23705070; DOI=10.7554/elife.00594;
RA   Banerjee A., Lee A., Campbell E., Mackinnon R.;
RT   "Structure of a pore-blocking toxin in complex with a eukaryotic voltage-
RT   dependent K(+) channel.";
RL   Elife 2:E00594-E00594(2013).
CC   -!- FUNCTION: Voltage-gated potassium channel that mediates transmembrane
CC       potassium transport in excitable membranes, primarily in the brain and
CC       the central nervous system, but also in the cardiovascular system.
CC       Prevents aberrant action potential firing and regulates neuronal
CC       output. Forms tetrameric potassium-selective channels through which
CC       potassium ions pass in accordance with their electrochemical gradient.
CC       The channel alternates between opened and closed conformations in
CC       response to the voltage difference across the membrane
CC       (PubMed:12151401, PubMed:21602278, PubMed:24472174). Can form
CC       functional homotetrameric channels and heterotetrameric channels that
CC       contain variable proportions of KCNA1, KCNA2, KCNA4, KCNA5, KCNA6,
CC       KCNA7, and possibly other family members as well; channel properties
CC       depend on the type of alpha subunits that are part of the channel
CC       (PubMed:15618540, PubMed:20805574, PubMed:23725331, PubMed:8495559).
CC       Channel properties are modulated by cytoplasmic beta subunits that
CC       regulate the subcellular location of the alpha subunits and promote
CC       rapid inactivation of delayed rectifier potassium channels
CC       (PubMed:18003609, PubMed:19713757). In vivo, membranes probably contain
CC       a mixture of heteromeric potassium channel complexes, making it
CC       difficult to assign currents observed in intact tissues to a particular
CC       potassium channel family member. Homotetrameric KCNA2 forms a delayed-
CC       rectifier potassium channel that opens in response to membrane
CC       depolarization, followed by slow spontaneous channel closure
CC       (PubMed:16770729, PubMed:1715584, PubMed:17766348, PubMed:18003609,
CC       PubMed:18638484, PubMed:19713757, PubMed:20089912). In contrast, a
CC       heteromultimer formed by KCNA2 and KCNA4 shows rapid inactivation
CC       (PubMed:8495559). Response to toxins that are selective for KCNA1,
CC       respectively for KCNA2, suggests that heteromeric potassium channels
CC       composed of both KCNA1 and KCNA2 play a role in pacemaking and regulate
CC       the output of deep cerebellar nuclear neurons (PubMed:23318870). KCNA2-
CC       containing channels play a presynaptic role and prevent
CC       hyperexcitability and aberrant action potential firing
CC       (PubMed:12777451). Response to toxins that are selective for KCNA2-
CC       containing potassium channels suggests that in Purkinje cells,
CC       dendritic subthreshold KCNA2-containing potassium channels prevent
CC       random spontaneous calcium spikes, suppressing dendritic
CC       hyperexcitability without hindering the generation of somatic action
CC       potentials, and thereby play an important role in motor coordination
CC       (PubMed:16210348). Plays a role in the induction of long-term
CC       potentiation of neuron excitability in the CA3 layer of the hippocampus
CC       (By similarity). May function as down-stream effector for G protein-
CC       coupled receptors and inhibit GABAergic inputs to basolateral amygdala
CC       neurons (PubMed:16306173). May contribute to the regulation of
CC       neurotransmitter release, such as gamma-aminobutyric acid (GABA)
CC       (PubMed:17869444). Contributes to the regulation of the axonal release
CC       of the neurotransmitter dopamine (PubMed:21647367). Reduced KCNA2
CC       expression plays a role in the perception of neuropathic pain after
CC       peripheral nerve injury, but not acute pain (PubMed:24472174). Plays a
CC       role in the regulation of the time spent in non-rapid eye movement
CC       (NREM) sleep (By similarity). {ECO:0000250|UniProtKB:P63141,
CC       ECO:0000269|PubMed:11007484, ECO:0000269|PubMed:12151401,
CC       ECO:0000269|PubMed:12177193, ECO:0000269|PubMed:12777451,
CC       ECO:0000269|PubMed:15618540, ECO:0000269|PubMed:16210348,
CC       ECO:0000269|PubMed:16770729, ECO:0000269|PubMed:1715584,
CC       ECO:0000269|PubMed:17766348, ECO:0000269|PubMed:18003609,
CC       ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:18638484,
CC       ECO:0000269|PubMed:20089912, ECO:0000269|PubMed:20805574,
CC       ECO:0000269|PubMed:21602278, ECO:0000269|PubMed:23318870,
CC       ECO:0000269|PubMed:24472174, ECO:0000269|PubMed:2555158,
CC       ECO:0000269|PubMed:7544443, ECO:0000269|PubMed:8495559, ECO:0000305,
CC       ECO:0000305|PubMed:12177193, ECO:0000305|PubMed:16306173,
CC       ECO:0000305|PubMed:17869444, ECO:0000305|PubMed:21647367}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=K(+)(in) = K(+)(out); Xref=Rhea:RHEA:29463, ChEBI:CHEBI:29103;
CC         Evidence={ECO:0000269|PubMed:1715584, ECO:0000269|PubMed:2555158,
CC         ECO:0000269|PubMed:7544443, ECO:0000269|PubMed:9635436};
CC   -!- ACTIVITY REGULATION: Inhibited by 4-aminopyridine (4-AP), dendrotoxin
CC       (DTX) and charybdotoxin (CTX), but not by tetraethylammonium (TEA)
CC       (PubMed:18638484, PubMed:2555158, PubMed:8495559). Inhibited by
CC       tityustoxin-K alpha (TsTX-Kalpha), a toxin that is highly specific for
CC       KCNA2 (PubMed:8355670). Inhibited by maurotoxin (PubMed:24472174).
CC       Inhibited by kappaM conotoxins kappaM-RIIIJ and kappaM-RIIIK (By
CC       similarity). {ECO:0000250|UniProtKB:P16389,
CC       ECO:0000269|PubMed:18638484, ECO:0000269|PubMed:20805574,
CC       ECO:0000269|PubMed:24472174, ECO:0000269|PubMed:2555158,
CC       ECO:0000269|PubMed:8355670, ECO:0000269|PubMed:8495559}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         Note=Homotetrameric channels activate rapidly, i.e within a few msec,
CC         but inactivation is very slow, with only a marginal decrease in
CC         conductance over several seconds. The voltage-dependence of
CC         activation and inactivation and other channel characteristics vary
CC         depending on the experimental conditions, the expression system,
CC         post-translational modifications and the presence or absence of
CC         ancillary subunits. For the activation of homotetrameric channels
CC         expressed in xenopus oocytes, the voltage at half-maximal amplitude
CC         is about -34 mV (PubMed:2555158). Unit channel conductance is about
CC         10 pS (PubMed:2555158). For the activation of homotetrameric channels
CC         expressed in Chinese hamster ovary (CHO) cells, the voltage at half-
CC         maximal amplitude is about -10 mV (PubMed:17324383).
CC         {ECO:0000269|PubMed:17324383, ECO:0000269|PubMed:2555158};
CC   -!- SUBUNIT: Homotetramer and heterotetramer with other channel-forming
CC       alpha subunits, such as KCNA1, KCNA4, KCNA5, KCNA6 and KCNA7
CC       (PubMed:10896669, PubMed:11007484, PubMed:12632190, PubMed:12777451,
CC       PubMed:15618540, PubMed:16002581, PubMed:18004376, PubMed:20534430,
CC       PubMed:8361540, PubMed:8495559). Channel activity is regulated by
CC       interaction with beta subunits, including KCNAB1 and KCNAB2
CC       (PubMed:16002581, PubMed:18003609, PubMed:18004376, PubMed:19713757,
CC       PubMed:20360102, PubMed:20534430, PubMed:23705070). Identified in a
CC       complex with KCNA1 and KCNAB2 (PubMed:11086297, PubMed:23318870).
CC       Identified in a complex with KCNA5 and KCNAB1 (By similarity).
CC       Identified in a complex with KCNA4 and FYN (By similarity). Interacts
CC       (via C-terminus) with the PDZ domains of DLG1 and DLG2
CC       (PubMed:7477295). Interacts with DLG4 (via PDZ domain)
CC       (PubMed:20089912, PubMed:7477295). Interacts with PTK2B
CC       (PubMed:11739373). Interacts (via C-terminus) with CTTN
CC       (PubMed:12151401). Interacts (via N-terminal cytoplasmic domain) with
CC       RHOA (GTP-bound form); this regulates channel activity by reducing
CC       location at the cell surface in response to CHRM1 activation
CC       (PubMed:9635436). Interacts with DRD2 (By similarity). Interacts with
CC       SIGMAR1; cocaine consumption leads to increased interaction (By
CC       similarity). Interacts with CNTNAP2 (PubMed:10624965). Interacts with
CC       ADAM22 (PubMed:20089912). Interacts with ADAM11 (By similarity).
CC       Intercts with LYNX1 (By similarity). {ECO:0000250|UniProtKB:P16389,
CC       ECO:0000250|UniProtKB:P63141, ECO:0000250|UniProtKB:Q09081,
CC       ECO:0000269|PubMed:10624965, ECO:0000269|PubMed:10896669,
CC       ECO:0000269|PubMed:11007484, ECO:0000269|PubMed:11086297,
CC       ECO:0000269|PubMed:11739373, ECO:0000269|PubMed:12151401,
CC       ECO:0000269|PubMed:12632190, ECO:0000269|PubMed:15618540,
CC       ECO:0000269|PubMed:16002581, ECO:0000269|PubMed:18004376,
CC       ECO:0000269|PubMed:19713757, ECO:0000269|PubMed:20089912,
CC       ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430,
CC       ECO:0000269|PubMed:23318870, ECO:0000269|PubMed:23705070,
CC       ECO:0000269|PubMed:7477295, ECO:0000269|PubMed:8361540,
CC       ECO:0000269|PubMed:8495559, ECO:0000269|PubMed:9635436, ECO:0000305}.
CC   -!- INTERACTION:
CC       P63142; P78352: DLG4; Xeno; NbExp=2; IntAct=EBI-631446, EBI-80389;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10896669,
CC       ECO:0000269|PubMed:12151401, ECO:0000269|PubMed:14713306,
CC       ECO:0000269|PubMed:15618540, ECO:0000269|PubMed:16770729,
CC       ECO:0000269|PubMed:1715584, ECO:0000269|PubMed:17766348,
CC       ECO:0000269|PubMed:18003609, ECO:0000269|PubMed:20089912,
CC       ECO:0000269|PubMed:20805574, ECO:0000269|PubMed:21602278,
CC       ECO:0000269|PubMed:23318870, ECO:0000269|PubMed:23725331,
CC       ECO:0000269|PubMed:24472174, ECO:0000269|PubMed:2555158,
CC       ECO:0000269|PubMed:7544443, ECO:0000269|PubMed:9635436,
CC       ECO:0000305|PubMed:11086297}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:12151401, ECO:0000269|PubMed:16002581,
CC       ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:20360102,
CC       ECO:0000269|PubMed:20534430, ECO:0000269|PubMed:23705070, ECO:0000305}.
CC       Membrane {ECO:0000269|PubMed:10624965, ECO:0000269|PubMed:16002581,
CC       ECO:0000269|PubMed:18004376, ECO:0000269|PubMed:18638484,
CC       ECO:0000269|PubMed:20089912, ECO:0000269|PubMed:20360102,
CC       ECO:0000269|PubMed:20534430, ECO:0000269|PubMed:23705070,
CC       ECO:0000269|PubMed:8361540}. Cell projection, axon
CC       {ECO:0000269|PubMed:10624965, ECO:0000269|PubMed:12177193,
CC       ECO:0000269|PubMed:12777451, ECO:0000269|PubMed:20089912,
CC       ECO:0000269|PubMed:21602278, ECO:0000269|PubMed:8361540}. Synapse
CC       {ECO:0000269|PubMed:8361540}. Synapse, synaptosome
CC       {ECO:0000250|UniProtKB:P63141}. Presynaptic cell membrane
CC       {ECO:0000250|UniProtKB:P63141}. Cell projection, dendrite
CC       {ECO:0000250|UniProtKB:P63141}. Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:10896669}. Cell projection, lamellipodium membrane
CC       {ECO:0000269|PubMed:12151401}. Endosome {ECO:0000269|PubMed:19403695}.
CC       Perikaryon {ECO:0000269|PubMed:23318870}. Cell junction, paranodal
CC       septate junction {ECO:0000250|UniProtKB:P63141}. Note=KCNA2 by itself
CC       is detected both at the endoplasmic reticulum and at the cell membrane.
CC       Coexpression with KCNA4 or with beta subunits promotes expression at
CC       the cell membrane (PubMed:10896669, PubMed:16770729, PubMed:18003609).
CC       Coexpression with KCNA1 inhibits cell surface expression
CC       (PubMed:10896669). Surface levels are regulated both by steady-state
CC       and stimulus-induced clathrin-dependent endocytosis (PubMed:19403695).
CC       Expression at the cell surface is down-regulated in response to CHRM1
CC       activation (PubMed:9635436). Expression at the cell surface is
CC       increased in response to the activation of beta-adrenergic receptors
CC       and increased cAMP levels (PubMed:18003609). Detected on presynaptic
CC       and postsynaptic axon segments (PubMed:12777451). In myelinated
CC       peripheral axons, clustered in the juxtaparadonal region and at an
CC       internodal line located along the mesaxon and below the Schmidt-
CC       Lanterman incisures (By similarity). {ECO:0000250|UniProtKB:P63141,
CC       ECO:0000269|PubMed:10896669, ECO:0000269|PubMed:12777451,
CC       ECO:0000269|PubMed:16770729, ECO:0000269|PubMed:18003609,
CC       ECO:0000269|PubMed:19403695, ECO:0000269|PubMed:9635436}.
CC   -!- TISSUE SPECIFICITY: Detected in neurons in dorsal root ganglion
CC       (PubMed:24472174). Detected in hippocampus neurons (PubMed:21602278).
CC       Detected on neurons of the anteroventral cochlear nucleus
CC       (PubMed:12777451). Detected in neurons of the medial nucleus of the
CC       trapezoid body (PubMed:12177193). Detected in neurons in the brain
CC       cortex (PubMed:14713306). Detected in axon tracts of the corpus
CC       callosum, specific terminal fields of the brain cortex neuropil,
CC       neurons in the medial entorhinal cortex, and in puncta representing
CC       mossy fiber terminals in the hippocampus mossy fiber tract; these
CC       puncta correspond to synapses made by dentate granule cells
CC       (PubMed:8361540). Detected in paranodal and juxtanodal zones in the
CC       central nervous system, including myelinated spinal cord
CC       (PubMed:11086297, PubMed:20089912). Detected in the juxtaparanodal
CC       region in optic nerve (PubMed:10624965). Detected at nerve terminal
CC       plexuses of basket cells in the cerebellum (at protein level)
CC       (PubMed:20089912, PubMed:7477295). Detected in brain (PubMed:2722779).
CC       Detected in heart atrium and ventricle (PubMed:1715584). Detected in
CC       renal arteries (PubMed:12632190). {ECO:0000269|PubMed:10624965,
CC       ECO:0000269|PubMed:11086297, ECO:0000269|PubMed:12177193,
CC       ECO:0000269|PubMed:12632190, ECO:0000269|PubMed:14713306,
CC       ECO:0000269|PubMed:1715584, ECO:0000269|PubMed:20089912,
CC       ECO:0000269|PubMed:21602278, ECO:0000269|PubMed:24472174,
CC       ECO:0000269|PubMed:2722779, ECO:0000269|PubMed:7477295,
CC       ECO:0000269|PubMed:8361540}.
CC   -!- INDUCTION: Up-regulated in brain cortex in response to ischemia (at
CC       protein level) (PubMed:14713306). Down-regulated in dorsal root
CC       ganglion neurons after peripheral nerve injury (at protein level)
CC       (PubMed:24472174). Down-regulated in pulmonary artery myocytes in
CC       response to chronic moderate hypoxia. {ECO:0000269|PubMed:14713306,
CC       ECO:0000269|PubMed:15151918, ECO:0000269|PubMed:24472174}.
CC   -!- DOMAIN: The cytoplasmic N-terminus is important for tetramerization.
CC       Interactions between the different subunits modulate the gating
CC       characteristics (PubMed:11007484). Besides, the cytoplasmic N-terminal
CC       domain mediates interaction with RHOA and thus is required for RHOA-
CC       mediated endocytosis (PubMed:9635436). {ECO:0000269|PubMed:11007484,
CC       ECO:0000269|PubMed:19403695, ECO:0000269|PubMed:9635436}.
CC   -!- DOMAIN: The transmembrane segment S4 functions as a voltage-sensor and
CC       is characterized by a series of positively charged amino acids at every
CC       third position. Channel opening and closing is effected by a
CC       conformation change that affects the position and orientation of the
CC       voltage-sensor paddle formed by S3 and S4 within the membrane. A
CC       transmembrane electric field that is positive inside would push the
CC       positively charged S4 segment outwards, thereby opening the pore, while
CC       a field that is negative inside would pull the S4 segment inwards and
CC       close the pore. Changes in the position and orientation of S4 are then
CC       transmitted to the activation gate formed by the inner helix bundle via
CC       the S4-S5 linker region. {ECO:0000305|PubMed:16002579,
CC       ECO:0000305|PubMed:20360102}.
CC   -!- PTM: Phosphorylated on tyrosine residues; phosphorylation increases in
CC       response to ischemia (PubMed:14713306). Phosphorylated on tyrosine
CC       residues by activated PTK2B/PYK2 (PubMed:7544443). Phosphorylation on
CC       tyrosine residues suppresses ion channel activity (PubMed:7544443).
CC       Phosphorylated on tyrosine residues in response to CHRM1 activation;
CC       this abolishes interaction with CTTN (PubMed:12151401). This is
CC       probably due to endocytosis of the phosphorylated channel subunits.
CC       Phosphorylated on serine residues in response to increased cAMP levels;
CC       phosphorylation is apparently not catalyzed by PKA (PubMed:18003609).
CC       {ECO:0000269|PubMed:12151401, ECO:0000269|PubMed:14713306,
CC       ECO:0000269|PubMed:18003609, ECO:0000269|PubMed:7544443}.
CC   -!- PTM: N-glycosylated, with complex, sialylated N-glycans.
CC       {ECO:0000269|PubMed:10896669, ECO:0000269|PubMed:16770729}.
CC   -!- MISCELLANEOUS: The delay or D-type current observed in hippocampus
CC       pyramidal neurons is probably mediated by potassium channels containing
CC       KCNA2 plus KCNA1 or other family members. It is activated at about -50
CC       mV, i.e. below the action potential threshold, and is characterized by
CC       slow inactivation, extremely slow recovery from inactivation,
CC       sensitivity to dendrotoxin (DTX) and to 4-aminopyridine (4-AP).
CC       {ECO:0000305|PubMed:17917103}.
CC   -!- SIMILARITY: Belongs to the potassium channel family. A (Shaker) (TC
CC       1.A.1.2) subfamily. Kv1.2/KCNA2 sub-subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J04731; AAA40819.1; -; mRNA.
DR   EMBL; X16003; CAA34134.1; -; mRNA.
DR   EMBL; M74449; AAA19867.1; -; mRNA.
DR   PIR; A33814; A33814.
DR   RefSeq; NP_037102.1; NM_012970.3.
DR   RefSeq; XP_006233194.1; XM_006233132.3.
DR   RefSeq; XP_006233195.1; XM_006233133.3.
DR   RefSeq; XP_006233196.1; XM_006233134.3.
DR   RefSeq; XP_006233197.1; XM_006233135.3.
DR   RefSeq; XP_008759593.1; XM_008761371.2.
DR   PDB; 1DSX; X-ray; 1.60 A; A/B/C/D/E/F/G/H=33-119.
DR   PDB; 1QDV; X-ray; 1.60 A; A/B/C/D=33-131.
DR   PDB; 1QDW; X-ray; 2.10 A; A/B/C/D/E/F/G/H=33-119.
DR   PDB; 2A79; X-ray; 2.90 A; B=1-499.
DR   PDB; 2R9R; X-ray; 2.40 A; B/H=1-499.
DR   PDB; 3LNM; X-ray; 2.90 A; B/D=1-266, B/D=303-499.
DR   PDB; 3LUT; X-ray; 2.90 A; B=1-499.
DR   PDB; 4JTA; X-ray; 2.50 A; B/Q=1-266, B/Q=304-499.
DR   PDB; 4JTC; X-ray; 2.56 A; B/H=1-266, B/H=304-499.
DR   PDB; 4JTD; X-ray; 2.54 A; B/H=1-266, B/H=304-499.
DR   PDB; 5WIE; X-ray; 3.30 A; B/H=1-42.
DR   PDB; 6EBK; EM; 3.30 A; B/D/F/H=1-266, B/D/F/H=305-499.
DR   PDB; 6EBL; EM; 3.00 A; B/D/F/H=1-266, B/D/F/H=305-499.
DR   PDB; 6EBM; EM; 4.00 A; B/D/F/H=1-266, B/D/F/H=305-499.
DR   PDB; 7SIT; X-ray; 3.32 A; B/D=1-499.
DR   PDB; 7SIZ; X-ray; 3.10 A; B/D=1-499.
DR   PDBsum; 1DSX; -.
DR   PDBsum; 1QDV; -.
DR   PDBsum; 1QDW; -.
DR   PDBsum; 2A79; -.
DR   PDBsum; 2R9R; -.
DR   PDBsum; 3LNM; -.
DR   PDBsum; 3LUT; -.
DR   PDBsum; 4JTA; -.
DR   PDBsum; 4JTC; -.
DR   PDBsum; 4JTD; -.
DR   PDBsum; 5WIE; -.
DR   PDBsum; 6EBK; -.
DR   PDBsum; 6EBL; -.
DR   PDBsum; 6EBM; -.
DR   PDBsum; 7SIT; -.
DR   PDBsum; 7SIZ; -.
DR   AlphaFoldDB; P63142; -.
DR   EMDB; EMD-9024; -.
DR   EMDB; EMD-9025; -.
DR   EMDB; EMD-9026; -.
DR   SMR; P63142; -.
DR   BioGRID; 247501; 5.
DR   CORUM; P63142; -.
DR   IntAct; P63142; 4.
DR   STRING; 10116.ENSRNOP00000075852; -.
DR   BindingDB; P63142; -.
DR   ChEMBL; CHEMBL4105982; -.
DR   DrugCentral; P63142; -.
DR   GuidetoPHARMACOLOGY; 539; -.
DR   GlyCosmos; P63142; 1 site, No reported glycans.
DR   GlyGen; P63142; 1 site.
DR   iPTMnet; P63142; -.
DR   PhosphoSitePlus; P63142; -.
DR   PaxDb; 10116-ENSRNOP00000042653; -.
DR   ABCD; P63142; 3 sequenced antibodies.
DR   Ensembl; ENSRNOT00000092450.2; ENSRNOP00000075852.1; ENSRNOG00000018285.7.
DR   Ensembl; ENSRNOT00000100022.1; ENSRNOP00000089201.1; ENSRNOG00000018285.7.
DR   Ensembl; ENSRNOT00000108979.1; ENSRNOP00000079590.1; ENSRNOG00000018285.7.
DR   Ensembl; ENSRNOT00000116262.1; ENSRNOP00000090952.1; ENSRNOG00000018285.7.
DR   Ensembl; ENSRNOT00055034634; ENSRNOP00055028059; ENSRNOG00055020280.
DR   Ensembl; ENSRNOT00055034637; ENSRNOP00055028062; ENSRNOG00055020280.
DR   Ensembl; ENSRNOT00055034641; ENSRNOP00055028065; ENSRNOG00055020280.
DR   Ensembl; ENSRNOT00055034645; ENSRNOP00055028070; ENSRNOG00055020280.
DR   Ensembl; ENSRNOT00060051941; ENSRNOP00060043198; ENSRNOG00060029911.
DR   Ensembl; ENSRNOT00060051956; ENSRNOP00060043210; ENSRNOG00060029911.
DR   Ensembl; ENSRNOT00060051963; ENSRNOP00060043217; ENSRNOG00060029911.
DR   Ensembl; ENSRNOT00060051970; ENSRNOP00060043223; ENSRNOG00060029911.
DR   Ensembl; ENSRNOT00065039166; ENSRNOP00065031816; ENSRNOG00065022931.
DR   Ensembl; ENSRNOT00065039168; ENSRNOP00065031817; ENSRNOG00065022931.
DR   Ensembl; ENSRNOT00065039175; ENSRNOP00065031822; ENSRNOG00065022931.
DR   Ensembl; ENSRNOT00065039180; ENSRNOP00065031826; ENSRNOG00065022931.
DR   GeneID; 25468; -.
DR   KEGG; rno:25468; -.
DR   AGR; RGD:2950; -.
DR   CTD; 3737; -.
DR   RGD; 2950; Kcna2.
DR   eggNOG; KOG1545; Eukaryota.
DR   GeneTree; ENSGT00940000158688; -.
DR   HOGENOM; CLU_011722_4_0_1; -.
DR   InParanoid; P63142; -.
DR   OMA; VNHSTED; -.
DR   OrthoDB; 1478695at2759; -.
DR   PhylomeDB; P63142; -.
DR   TreeFam; TF313103; -.
DR   Reactome; R-RNO-1296072; Voltage gated Potassium channels.
DR   EvolutionaryTrace; P63142; -.
DR   PRO; PR:P63142; -.
DR   Proteomes; UP000002494; Chromosome 2.
DR   Bgee; ENSRNOG00000018285; Expressed in cerebellum and 12 other cell types or tissues.
DR   ExpressionAtlas; P63142; baseline and differential.
DR   GO; GO:0030424; C:axon; ISO:RGD.
DR   GO; GO:0043194; C:axon initial segment; ISO:RGD.
DR   GO; GO:0043679; C:axon terminus; ISS:UniProtKB.
DR   GO; GO:0044305; C:calyx of Held; IDA:SynGO.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0044224; C:juxtaparanode region of axon; IDA:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
DR   GO; GO:0031258; C:lamellipodium membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IBA:GO_Central.
DR   GO; GO:0032809; C:neuronal cell body membrane; ISS:UniProtKB.
DR   GO; GO:0033010; C:paranodal junction; IEA:UniProtKB-SubCell.
DR   GO; GO:0043204; C:perikaryon; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IMP:UniProtKB.
DR   GO; GO:0045211; C:postsynaptic membrane; IDA:SynGO.
DR   GO; GO:0034705; C:potassium channel complex; IDA:UniProtKB.
DR   GO; GO:0042734; C:presynaptic membrane; IDA:SynGO.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; IDA:UniProtKB.
DR   GO; GO:0005251; F:delayed rectifier potassium channel activity; IMP:UniProtKB.
DR   GO; GO:0019894; F:kinesin binding; IPI:RGD.
DR   GO; GO:0015271; F:outward rectifier potassium channel activity; IMP:RGD.
DR   GO; GO:1905030; F:voltage-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential; IDA:SynGO.
DR   GO; GO:0099508; F:voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential; IDA:SynGO.
DR   GO; GO:0005249; F:voltage-gated potassium channel activity; IDA:UniProtKB.
DR   GO; GO:0001508; P:action potential; IBA:GO_Central.
DR   GO; GO:0021987; P:cerebral cortex development; IEP:RGD.
DR   GO; GO:0022038; P:corpus callosum development; IEP:RGD.
DR   GO; GO:0019228; P:neuronal action potential; IMP:UniProtKB.
DR   GO; GO:0021554; P:optic nerve development; IEP:RGD.
DR   GO; GO:0021633; P:optic nerve structural organization; ISO:RGD.
DR   GO; GO:0097623; P:potassium ion export across plasma membrane; IMP:RGD.
DR   GO; GO:0071805; P:potassium ion transmembrane transport; IMP:UniProtKB.
DR   GO; GO:0051260; P:protein homooligomerization; IEA:InterPro.
DR   GO; GO:0045188; P:regulation of circadian sleep/wake cycle, non-REM sleep; ISO:RGD.
DR   GO; GO:0014059; P:regulation of dopamine secretion; ISS:UniProtKB.
DR   GO; GO:0019233; P:sensory perception of pain; IMP:UniProtKB.
DR   Gene3D; 1.10.287.70; -; 1.
DR   Gene3D; 1.20.120.350; Voltage-gated potassium channels. Chain C; 1.
DR   InterPro; IPR000210; BTB/POZ_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR003968; K_chnl_volt-dep_Kv.
DR   InterPro; IPR003972; K_chnl_volt-dep_Kv1.
DR   InterPro; IPR004049; K_chnl_volt-dep_Kv1.2.
DR   InterPro; IPR011333; SKP1/BTB/POZ_sf.
DR   InterPro; IPR003131; T1-type_BTB.
DR   InterPro; IPR027359; Volt_channel_dom_sf.
DR   PANTHER; PTHR11537:SF23; POTASSIUM VOLTAGE-GATED CHANNEL SUBFAMILY A MEMBER 2; 1.
DR   PANTHER; PTHR11537; VOLTAGE-GATED POTASSIUM CHANNEL; 1.
DR   Pfam; PF02214; BTB_2; 1.
DR   Pfam; PF00520; Ion_trans; 1.
DR   PRINTS; PR00169; KCHANNEL.
DR   PRINTS; PR01509; KV12CHANNEL.
DR   PRINTS; PR01491; KVCHANNEL.
DR   PRINTS; PR01496; SHAKERCHANEL.
DR   SMART; SM00225; BTB; 1.
DR   SUPFAM; SSF54695; POZ domain; 1.
DR   SUPFAM; SSF81324; Voltage-gated potassium channels; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell junction; Cell membrane; Cell projection;
KW   Endoplasmic reticulum; Endosome; Glycoprotein; Ion channel; Ion transport;
KW   Lipoprotein; Membrane; Palmitate; Phosphoprotein; Potassium;
KW   Potassium channel; Potassium transport; Reference proteome; Synapse;
KW   Synaptosome; Transmembrane; Transmembrane helix; Transport;
KW   Voltage-gated channel.
FT   CHAIN           1..499
FT                   /note="Potassium voltage-gated channel subfamily A member
FT                   2"
FT                   /id="PRO_0000053975"
FT   TOPO_DOM        1..160
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:18004376,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430"
FT   TRANSMEM        161..182
FT                   /note="Helical; Name=Segment S1"
FT                   /evidence="ECO:0000269|PubMed:18004376,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430"
FT   TOPO_DOM        183..221
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:18004376,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430,
FT                   ECO:0000305|PubMed:12151401"
FT   TRANSMEM        222..243
FT                   /note="Helical; Name=Segment S2"
FT                   /evidence="ECO:0000269|PubMed:18004376,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430"
FT   TOPO_DOM        244..254
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:18004376,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430"
FT   TRANSMEM        255..275
FT                   /note="Helical; Name=Segment S3"
FT                   /evidence="ECO:0000269|PubMed:18004376,
FT                   ECO:0000269|PubMed:20534430"
FT   TOPO_DOM        276..289
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:18004376,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430"
FT   TRANSMEM        290..310
FT                   /note="Helical; Voltage-sensor; Name=Segment S4"
FT                   /evidence="ECO:0000269|PubMed:18004376,
FT                   ECO:0000269|PubMed:20534430"
FT   TOPO_DOM        311..325
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:18004376,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430"
FT   TRANSMEM        326..347
FT                   /note="Helical; Name=Segment S5"
FT                   /evidence="ECO:0000269|PubMed:18004376,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430"
FT   TOPO_DOM        348..361
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:18004376,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430"
FT   INTRAMEM        362..373
FT                   /note="Helical; Name=Pore helix"
FT                   /evidence="ECO:0000269|PubMed:18004376,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430"
FT   INTRAMEM        374..381
FT                   /evidence="ECO:0000269|PubMed:18004376,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430"
FT   TOPO_DOM        382..388
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:18004376,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430"
FT   TRANSMEM        389..417
FT                   /note="Helical; Name=Segment S6"
FT                   /evidence="ECO:0000269|PubMed:18004376,
FT                   ECO:0000269|PubMed:20360102, ECO:0000269|PubMed:20534430"
FT   TOPO_DOM        418..499
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:12151401, ECO:0000305"
FT   REGION          1..125
FT                   /note="Tetramerization domain"
FT                   /evidence="ECO:0000305|PubMed:11007484"
FT   REGION          1..26
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          312..325
FT                   /note="S4-S5 linker"
FT                   /evidence="ECO:0000305|PubMed:16002579"
FT   MOTIF           374..379
FT                   /note="Selectivity filter"
FT                   /evidence="ECO:0000305"
FT   MOTIF           497..499
FT                   /note="PDZ-binding"
FT                   /evidence="ECO:0000269|PubMed:7477295"
FT   SITE            252
FT                   /note="Important for normal, slow channel gating"
FT                   /evidence="ECO:0000269|PubMed:17766348"
FT   SITE            381
FT                   /note="Important for binding with the scorpion
FT                   mesomartoxin; when the scorpion mesomartoxin-rKv1.2/KCNA2
FT                   interaction is modeled, this residue is close to the 'Y-57'
FT                   residue of the toxin"
FT                   /evidence="ECO:0000305|PubMed:25514171"
FT   MOD_RES         429
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P63141"
FT   MOD_RES         434
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P63141"
FT   MOD_RES         440
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:18003609,
FT                   ECO:0007744|PubMed:22673903"
FT   MOD_RES         441
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         449
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:18003609,
FT                   ECO:0000269|PubMed:21602278"
FT   MOD_RES         458
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000305|PubMed:21602278"
FT   MOD_RES         468
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   LIPID           244
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        207
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:16770729"
FT   MUTAGEN         34
FT                   /note="R->L: No effect on channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         38
FT                   /note="N->A: Alters voltage-sensitive channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         40
FT                   /note="S->A: No effect on channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         41
FT                   /note="G->A: Loss of channel activity."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         42
FT                   /note="L->A: No effect on channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         43
FT                   /note="R->L: No effect on channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         44
FT                   /note="F->A: Alters voltage-sensitive channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         45
FT                   /note="E->A: Loss of channel activity."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         46
FT                   /note="T->D: Impairs protein folding. Loss of
FT                   tetramerization."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         46
FT                   /note="T->V,A: No effect on tetramerization. Alters
FT                   voltage-sensitive channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         46
FT                   /note="T->V: Abolishes interaction with KCNAB2 and strongly
FT                   reduces cell surface expression. No effect phosphorylation
FT                   in response to increased cAMP levels."
FT                   /evidence="ECO:0000269|PubMed:18003609"
FT   MUTAGEN         47
FT                   /note="Q->A: No effect on channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         50
FT                   /note="T->A: Alters voltage-sensitive channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         70
FT                   /note="D->A: No effect on channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         73
FT                   /note="R->A: No effect on channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         75
FT                   /note="E->A: No effect on channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         77
FT                   /note="F->W: Alters voltage-sensitive channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         79
FT                   /note="D->N: Alters voltage-sensitive channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         81
FT                   /note="N->A: No effect on channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         82
FT                   /note="R->A: Loss of channel activity."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         86
FT                   /note="D->A: Alters voltage-sensitive channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         89
FT                   /note="L->A: No effect on channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         90
FT                   /note="Y->A: No effect on channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         93
FT                   /note="Q->A: Loss of channel activity."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         97
FT                   /note="R->A: No effect on channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         99
FT                   /note="R->A: No effect on channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         102
FT                   /note="V->T: Alters voltage-sensitive channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         103
FT                   /note="N->A: No effect on channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         105
FT                   /note="P->A: No effect on channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         107
FT                   /note="D->A: Alters voltage-sensitive channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         108
FT                   /note="I->A: No effect on channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         111
FT                   /note="E->A: Alters voltage-sensitive channel opening."
FT                   /evidence="ECO:0000269|PubMed:11007484"
FT   MUTAGEN         207
FT                   /note="N->Q: Loss of glycosylation site."
FT                   /evidence="ECO:0000269|PubMed:16770729"
FT   MUTAGEN         252
FT                   /note="T->R: Changes channel gating from a predominantly
FT                   slow mode to a much more rapid mode."
FT                   /evidence="ECO:0000269|PubMed:17766348"
FT   MUTAGEN         267..302
FT                   /note="FITLGTELAEKPEDAQQGQQAMSLAILRVIRLVRVF->YVTIFLTESNKSVL
FT                   QFQNVRRVVQIFRIM: In paddle chimera; changes channel
FT                   activation to less negative voltage values and renders the
FT                   channel susceptible to inhibition by the spider toxin
FT                   VsTx1."
FT                   /evidence="ECO:0000269|PubMed:18638484"
FT   MUTAGEN         356
FT                   /note="S->A: Impairs N-glycosylation and abolishes
FT                   expression at the cell surface."
FT                   /evidence="ECO:0000269|PubMed:16770729"
FT   MUTAGEN         360
FT                   /note="S->A: No effect on N-glycosylation. Abolishes
FT                   channel activity of the homotetramer, but retains channel
FT                   activity in the presence of a beta subunit."
FT                   /evidence="ECO:0000269|PubMed:16770729"
FT   MUTAGEN         381
FT                   /note="V->Y: Confers sensitivity to inhibition by
FT                   tetraethylammonium (TEA)."
FT                   /evidence="ECO:0000269|PubMed:23725331"
FT   MUTAGEN         383
FT                   /note="T->A: Impairs N-glycosylation and abolishes
FT                   expression at the cell surface."
FT                   /evidence="ECO:0000269|PubMed:16770729"
FT   MUTAGEN         415
FT                   /note="Y->F: Nearly abolishes interaction with CTTN; when
FT                   associated with F-417."
FT                   /evidence="ECO:0000269|PubMed:12151401"
FT   MUTAGEN         417
FT                   /note="Y->F: Nearly abolishes interaction with CTTN; when
FT                   associated with F-415. Strongly reduces channel activity."
FT                   /evidence="ECO:0000269|PubMed:12151401"
FT   MUTAGEN         440
FT                   /note="S->A: Strongly reduces cell surface expression.
FT                   Abolishes phosphorylation in response to increased cAMP
FT                   levels."
FT                   /evidence="ECO:0000269|PubMed:18003609"
FT   MUTAGEN         449
FT                   /note="S->A: Strongly reduces cell surface expression.
FT                   Abolishes phosphorylation in response to increased cAMP
FT                   levels."
FT                   /evidence="ECO:0000269|PubMed:18003609"
FT   MUTAGEN         458
FT                   /note="Y->A: Impairs clustering on axon membranes."
FT                   /evidence="ECO:0000269|PubMed:21602278"
FT   CONFLICT        411
FT                   /note="S -> F (in Ref. 4; AAA19867)"
FT                   /evidence="ECO:0000305"
FT   STRAND          34..39
FT                   /evidence="ECO:0007829|PDB:1DSX"
FT   STRAND          42..47
FT                   /evidence="ECO:0007829|PDB:1DSX"
FT   HELIX           48..52
FT                   /evidence="ECO:0007829|PDB:1DSX"
FT   TURN            58..60
FT                   /evidence="ECO:0007829|PDB:1DSX"
FT   HELIX           62..66
FT                   /evidence="ECO:0007829|PDB:1DSX"
FT   TURN            71..74
FT                   /evidence="ECO:0007829|PDB:1DSX"
FT   STRAND          75..78
FT                   /evidence="ECO:0007829|PDB:1DSX"
FT   TURN            82..84
FT                   /evidence="ECO:0007829|PDB:1QDW"
FT   HELIX           85..93
FT                   /evidence="ECO:0007829|PDB:1DSX"
FT   HELIX           106..116
FT                   /evidence="ECO:0007829|PDB:1DSX"
FT   HELIX           120..130
FT                   /evidence="ECO:0007829|PDB:1QDV"
FT   TURN            143..145
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   HELIX           146..149
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   TURN            150..154
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   STRAND          156..158
FT                   /evidence="ECO:0007829|PDB:4JTC"
FT   HELIX           160..182
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   HELIX           186..189
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   STRAND          190..192
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   TURN            193..196
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   HELIX           202..210
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   HELIX           221..241
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   STRAND          242..245
FT                   /evidence="ECO:0007829|PDB:7SIT"
FT   TURN            249..252
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   HELIX           254..261
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   HELIX           264..268
FT                   /evidence="ECO:0007829|PDB:7SIZ"
FT   HELIX           279..282
FT                   /evidence="ECO:0007829|PDB:3LUT"
FT   HELIX           291..299
FT                   /evidence="ECO:0007829|PDB:2A79"
FT   HELIX           305..309
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   HELIX           312..323
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   HELIX           325..351
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   HELIX           361..372
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   STRAND          378..380
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   HELIX           385..403
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   HELIX           406..418
FT                   /evidence="ECO:0007829|PDB:4JTA"
SQ   SEQUENCE   499 AA;  56701 MW;  A8FEA6F3F59AF42A CRC64;
     MTVATGDPVD EAAALPGHPQ DTYDPEADHE CCERVVINIS GLRFETQLKT LAQFPETLLG
     DPKKRMRYFD PLRNEYFFDR NRPSFDAILY YYQSGGRLRR PVNVPLDIFS EEIRFYELGE
     EAMEMFREDE GYIKEEERPL PENEFQRQVW LLFEYPESSG PARIIAIVSV MVILISIVSF
     CLETLPIFRD ENEDMHGGGV TFHTYSNSTI GYQQSTSFTD PFFIVETLCI IWFSFEFLVR
     FFACPSKAGF FTNIMNIIDI VAIIPYFITL GTELAEKPED AQQGQQAMSL AILRVIRLVR
     VFRIFKLSRH SKGLQILGQT LKASMRELGL LIFFLFIGVI LFSSAVYFAE ADERDSQFPS
     IPDAFWWAVV SMTTVGYGDM VPTTIGGKIV GSLCAIAGVL TIALPVPVIV SNFNYFYHRE
     TEGEEQAQYL QVTSCPKIPS SPDLKKSRSA STISKSDYME IQEGVNNSNE DFREENLKTA
     NCTLANTNYV NITKMLTDV
//
